TY  - JOUR
A1  - Rieger, C. T.
A1  - Liss, B.
A1  - Mellinghoff, S.
A1  - Buchheidt, D.
A1  - Cornely, O. A.
A1  - Egerer, G.
A1  - Heinz, W. J.
A1  - Hentrich, M.
A1  - Maschmeyer, G.
A1  - Mayer, K.
A1  - Sandherr, M.
A1  - Silling, G.
A1  - Ullmann, A.
A1  - Vehreschild, M. J. G. T.
A1  - von Lilienfeld-Toal, M.
A1  - Wolf, H. H.
A1  - Lehners, N.
T1  - Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)
JF  - Annals of Oncology
N2  - Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing currently available data and applying evidence-based medicine criteria.
KW  - infection
KW  - anti-infective vaccination
KW  - cancer
KW  - immunosuppression
KW  - autologous stem cell transplantation
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226196
VL  - 29
IS  - 6
ER  - 
TY  - JOUR
A1  - Nadella, Vinod
A1  - Mohanty, Aparna
A1  - Sharma, Lalita
A1  - Yellaboina, Sailu
A1  - Mollenkopf, Hans-Joachim
A1  - Mazumdar, Varadendra Balaji
A1  - Palaparthi, Ramesh
A1  - Mylavarapu, Madhavi B.
A1  - Maurya, Radheshyam
A1  - Kurukuti, Sreenivasulu
A1  - Rudel, Thomas
A1  - Prakash, Hridayesh
T1  - Inhibitors of Apoptosis Protein Antagonists (Smac Mimetic Compounds) Control Polarization of Macrophages during Microbial Challenge and Sterile Inflammatory Responses
JF  - Frontiers in Immunology
N2  - Apoptosis is a physiological cell death process essential for development, tissue homeostasis, and for immune defense of multicellular animals. Inhibitors of apoptosis proteins (IAPs) regulate apoptosis in response to various cellular assaults. Using both genetic and pharmacological approaches we demonstrate here that the IAPs not only support opportunistic survival of intracellular human pathogens like Chlamydia pneumoniae but also control plasticity of iNOS+ M1 macrophage during the course of infection and render them refractory for immune stimulation. Treatment of Th1 primed macrophages with birinapant (IAP-specific antagonist) inhibited NO generation and relevant proteins involved in innate immune signaling. Accordingly, birinapant promoted hypoxia, angiogenesis, and tumor-induced M2 polarization of iNOS+ M1 macrophages. Interestingly, birinapant-driven changes in immune signaling were accompanied with changes in the expression of various proteins involved in the metabolism, and thus revealing the new role of IAPs in immune metabolic reprogramming in committed macrophages. Taken together, our study reveals the significance of IAP targeting approaches (Smac mimetic compounds) for the management of infectious and inflammatory diseases relying on macrophage plasticity.
KW  - apoptosis
KW  - macrophages immunobiology
KW  - inflammation mediators
KW  - polarization
KW  - infection
KW  - hypothalamus
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-197484
SN  - 1664-3224
VL  - 8
IS  - 1792
ER  - 
TY  - JOUR
A1  - Strobel, Lea
A1  - Johswich, Kay O.
T1  - Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of Neisseria meningitidis infection
JF  - Scientific Reports
N2  - Neisseria meningitidis (meningococcus) causes invasive diseases such as meningitis or septicaemia. Ex vivo infection of human whole blood is a valuable tool to study meningococcal virulence factors and the host innate immune responses. In order to consider effects of cellular mediators, the coagulation cascade must be inhibited to avoid clotting. There is considerable variation in the anticoagulants used among studies of N. meningitidis whole blood infections, featuring citrate, heparin or derivatives of hirudin, a polypeptide from leech saliva. Here, we compare the influence of these three different anticoagulants, and additionally Mg/EGTA, on host innate immune responses as well as on viability of N. meningitidis strains isolated from healthy carriers and disease cases, reflecting different sequence types and capsule phenotypes. We found that the anticoagulants significantly impact on cellular responses and, strain-dependently, also on bacterial survival. Hirudin does not inhibit complement and is therefore superior over the other anticoagulants; indeed hirudin-plasma most closely reflects the characteristics of serum during N. meningitidis infection. We further demonstrate the impact of heparin on complement activation on N. meningitidis and its consequences on meningococcal survival in immune sera, which appears to be independent of the heparin binding antigens Opc and NHBA.
KW  - infection
KW  - pathogens
KW  - Neisseria meningitidis
KW  - anticoagulants
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176226
VL  - 8
IS  - 10225
ER  -